Seres Therapeutics’ (MCRB) “Market Perform” Rating Reiterated at Chardan Capital

Chardan Capital reissued their market perform rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note published on Thursday, AnalystRatings.com reports. Chardan Capital currently has a $12.50 price objective on the biotechnology company’s stock.

A number of other research analysts have also issued reports on MCRB. Zacks Investment Research upgraded shares of Seres Therapeutics from a hold rating to a buy rating and set a $6.25 price objective for the company in a report on Saturday, May 30th. HC Wainwright reissued a buy rating and set a $8.00 target price on shares of Seres Therapeutics in a research report on Monday, March 23rd. ValuEngine raised shares of Seres Therapeutics from a hold rating to a buy rating in a research report on Thursday, April 2nd. Oppenheimer decreased their target price on shares of Seres Therapeutics from $8.00 to $7.00 and set an outperform rating for the company in a research report on Tuesday, March 31st. Finally, Canaccord Genuity reissued a buy rating and set a $11.00 target price on shares of Seres Therapeutics in a research report on Friday, May 8th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $8.13.

Shares of NASDAQ MCRB opened at $4.75 on Thursday. The company has a 50 day simple moving average of $4.93 and a 200 day simple moving average of $3.87. The firm has a market cap of $357.19 million, a PE ratio of -4.75 and a beta of 1.15. Seres Therapeutics has a 1 year low of $2.15 and a 1 year high of $6.59.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.01 million. Analysts predict that Seres Therapeutics will post -1.01 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Citigroup Inc. grew its position in shares of Seres Therapeutics by 15.0% during the 1st quarter. Citigroup Inc. now owns 15,802 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,060 shares during the period. Federated Hermes Inc. grew its position in shares of Seres Therapeutics by 160.0% during the 1st quarter. Federated Hermes Inc. now owns 1,028,800 shares of the biotechnology company’s stock worth $3,673,000 after buying an additional 633,135 shares during the period. JPMorgan Chase & Co. grew its position in shares of Seres Therapeutics by 93.0% during the 1st quarter. JPMorgan Chase & Co. now owns 1,045,655 shares of the biotechnology company’s stock worth $3,734,000 after buying an additional 503,770 shares during the period. Barclays PLC grew its position in shares of Seres Therapeutics by 85.1% during the 4th quarter. Barclays PLC now owns 36,539 shares of the biotechnology company’s stock worth $126,000 after buying an additional 16,802 shares during the period. Finally, Geode Capital Management LLC grew its position in Seres Therapeutics by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 620,935 shares of the biotechnology company’s stock valued at $2,142,000 after purchasing an additional 73,073 shares during the period. 93.42% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Read More: Futures Contract

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.